tetano
Editor, Senior Moderator
Transplant Proc
. 2021 Nov 12;S0041-1345(21)00796-X.
doi: 10.1016/j.transproceed.2021.11.003. Online ahead of print.
Vaccine Breakthrough Severe COVID-19 in a Lung Recipient
Muhammet Ali Beyoglu[SUP] 1 [/SUP], Mehmet Furkan Sahin[SUP] 2 [/SUP], Sinan Turkkan[SUP] 2 [/SUP], Fatmanur Celik Basaran[SUP] 2 [/SUP], Alkin Yazicioglu[SUP] 2 [/SUP], Serife Gokbulut Bektas[SUP] 3 [/SUP], Yasemin Tezer Tekce[SUP] 4 [/SUP], Erdal Yekeler[SUP] 2 [/SUP]
Affiliations
Abstract
The vaccines developed against severe acute respiratory syndrome coronavirus 2 are seen as the most crucial weapon in controlling the epidemic. It has been reported in early-stage vaccine studies that vaccines provide up to 95% protection against severe disease and mortality, even in the absence of symptomatic infection. Reports on vaccine breakthrough infections that developed after widespread vaccination are available in the literature. In addition to the general population, the course of vaccine breakthrough infections in immunocompromised patients is a matter of concern. This case report aimed to define severe coronavirus disease 2019 developing in a lung recipient who received 3 doses of inactivated virus vaccine.
. 2021 Nov 12;S0041-1345(21)00796-X.
doi: 10.1016/j.transproceed.2021.11.003. Online ahead of print.
Vaccine Breakthrough Severe COVID-19 in a Lung Recipient
Muhammet Ali Beyoglu[SUP] 1 [/SUP], Mehmet Furkan Sahin[SUP] 2 [/SUP], Sinan Turkkan[SUP] 2 [/SUP], Fatmanur Celik Basaran[SUP] 2 [/SUP], Alkin Yazicioglu[SUP] 2 [/SUP], Serife Gokbulut Bektas[SUP] 3 [/SUP], Yasemin Tezer Tekce[SUP] 4 [/SUP], Erdal Yekeler[SUP] 2 [/SUP]
Affiliations
- PMID: 34887098
- DOI: 10.1016/j.transproceed.2021.11.003
Abstract
The vaccines developed against severe acute respiratory syndrome coronavirus 2 are seen as the most crucial weapon in controlling the epidemic. It has been reported in early-stage vaccine studies that vaccines provide up to 95% protection against severe disease and mortality, even in the absence of symptomatic infection. Reports on vaccine breakthrough infections that developed after widespread vaccination are available in the literature. In addition to the general population, the course of vaccine breakthrough infections in immunocompromised patients is a matter of concern. This case report aimed to define severe coronavirus disease 2019 developing in a lung recipient who received 3 doses of inactivated virus vaccine.